Clinical trialNCT03005418CompletedPhase 2/PHASE3Interventional

Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

SponsorHumacyte, Inc.Enrollment72TraumaVascular System Injury

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the use of the Acellular Tissue Engineered Vessel (ATEV) in adults with vascular trauma below the neck who are undergoing vascular reconstructive surgery. There will be an extremity cohort and an torso cohort. All subjects will be implanted with an ATEV as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Shamik Parikh, MD
Humacyte, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Soroka Medical Center - Vascular Surgery Department
Beersheba, Israel
Shaare Zedek Medical Center
Jerusalem, Israel

United States

Jacob Medical Center at Uc San Diego
La Jolla, California, United States
Cedars-Sinai Medical Cener
Los Angeles, California, United States
Keck Hospital of University of Southern California (usc)
Los Angeles, California, United States
Uci Medical Center
Orange, California, United States
University California, Davis
Sacramento, California, United States
University of California San Diego (ucsd) Medical Center
San Diego, California, United States
Ernest E Moore Shock Trauma Center at Denver Health
Denver, Colorado, United States
Uf Health Jacksonville
Jacksonville, Florida, United States
Jackson South Medical Center
Miami, Florida, United States
Ryder Trauma Center
Miami, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Grady Memorial Hospital
Atlanta, Georgia, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
R Adams Cowley Baltimore Shock Trauma
Baltimore, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
Saint Louis University (slu)
St Louis, Missouri, United States
Cooper University Hospital
Camden, New Jersey, United States
Rutgers New Jersey Medical School
Newark, New Jersey, United States
Duke University Hospital
Durham, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, United States
Oregon Health & Science University
Portland, Oregon, United States
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
the University of Texas - Dell Medical School
Austin, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Acellular tissue engineered vessel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Sept 2018
Primary completion: 19 Sept 2023
Completion: 15 May 2026
Last update posted: 29 Jul 2026
Registered enrollment: 72
Registry id: NCT03005418

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.